{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T20:47:43Z","timestamp":1768164463243,"version":"3.49.0"},"publisher-location":"Singapore","reference-count":61,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789811915918","type":"print"},{"value":"9789811915925","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-981-19-1592-5_13","type":"book-chapter","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T05:03:09Z","timestamp":1652677389000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HDL\u00a0and\u00a0Kidney Diseases"],"prefix":"10.1007","author":[{"given":"Huanhuan","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"issue":"3","key":"13_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccl.2005.03.004","volume":"23","author":"WF Keane","year":"2005","unstructured":"Keane WF, Lyle PA (2005) Kidney disease and cardiovascular disease: implications of dyslipidemia. Cardiol Clin 23(3):363\u2013372","journal-title":"Cardiol Clin"},{"issue":"10","key":"13_CR2","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2215\/CJN.00380116","volume":"11","author":"TH Banh","year":"2016","unstructured":"Banh TH et al (2016) Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 11(10):1760\u20131768","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"13_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.semnephrol.2018.02.009","volume":"38","author":"CB Sethna","year":"2018","unstructured":"Sethna CB, Merchant K, Reyes A (2018) Cardiovascular disease risk in children with kidney disease. Semin Nephrol 38(3):298\u2013313","journal-title":"Semin Nephrol"},{"key":"13_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/B978-0-7020-4086-3.00026-6","volume":"119","author":"DS Liebeskind","year":"2014","unstructured":"Liebeskind DS (2014) Nephrotic syndrome. Handb Clin Neurol 119:405\u2013415","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"13_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1042\/CS20040095","volume":"107","author":"JG van den Berg","year":"2004","unstructured":"van den Berg JG, Weening JJ (2004) Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond) 107(2):125\u2013136","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"13_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","volume":"69","author":"V Audard","year":"2006","unstructured":"Audard V et al (2006) Minimal change nephrotic syndrome and classical Hodgkin\u2019s lymphoma: report of 21 cases and review of the literature. Kidney Int 69(12):2251\u20132260","journal-title":"Kidney Int"},{"issue":"12","key":"13_CR7","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/ndt\/gfu355","volume":"29","author":"RJ Maas","year":"2014","unstructured":"Maas RJ, Deegens JK, Wetzels JF (2014) Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant 29(12):2207\u20132216","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"13_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/ckj\/sfv090","volume":"8","author":"T Wada","year":"2015","unstructured":"Wada T, Nangaku M (2015) A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J 8(6):708\u2013715","journal-title":"Clin Kidney J"},{"issue":"4","key":"13_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","volume":"37","author":"ML Downie","year":"2017","unstructured":"Downie ML et al (2017) Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health 37(4):248\u2013258","journal-title":"Paediatr Int Child Health"},{"key":"13_CR10","doi-asserted-by":"crossref","unstructured":"(1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A report of the international study of kidney disease in children. Kidney Int 20(6):765\u2013771","DOI":"10.1038\/ki.1981.209"},{"key":"13_CR11","doi-asserted-by":"crossref","unstructured":"(1984) Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years\u2019 observation. Report of the international study of kidney disease in children. Pediatrics 73(4):497\u2013501","DOI":"10.1542\/peds.73.4.497"},{"issue":"12","key":"13_CR12","doi-asserted-by":"crossref","first-page":"1168.e1","DOI":"10.1016\/j.recesp.2011.09.014","volume":"64","author":"Z Reiner","year":"2011","unstructured":"Reiner Z et al (2011) ESC\/EAS guidelines for the management of dyslipidaemias. Rev Esp Cardiol 64(12):1168.e1\u20131168.e60","journal-title":"Rev Esp Cardiol"},{"issue":"5","key":"13_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker LA et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63(5):713\u2013735","journal-title":"Am J Kidney Dis"},{"issue":"10075","key":"13_CR14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC et al (2017) Chronic kidney disease. Lancet 389(10075):1238\u20131252","journal-title":"Lancet"},{"issue":"6","key":"13_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","volume":"14","author":"HJ Anders","year":"2018","unstructured":"Anders HJ et al (2018) CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 14(6):361\u2013377","journal-title":"Nat Rev Nephrol"},{"key":"13_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/5584_2016_84","volume":"956","author":"SM Hamrahian","year":"2017","unstructured":"Hamrahian SM, Falkner B (2017) Hypertension in chronic kidney disease. Adv Exp Med Biol 956:307\u2013325","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"13_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040270","volume":"4","author":"E Di Angelantonio","year":"2007","unstructured":"Di Angelantonio E et al (2007) Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 4(9):e270","journal-title":"PLoS Med"},{"issue":"10","key":"13_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050207","volume":"5","author":"V Perkovic","year":"2008","unstructured":"Perkovic V et al (2008) The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 5(10):e207","journal-title":"PLoS Med"},{"key":"13_CR19","unstructured":"(2005) K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45(4 Suppl 3):S1\u2013S153"},{"key":"13_CR20","first-page":"CD008834","volume":"2","author":"SC Palmer","year":"2013","unstructured":"Palmer SC et al (2013) Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2:CD008834","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"13_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer SC et al (2012) Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157(4):263\u2013275","journal-title":"Ann Intern Med"},{"issue":"1","key":"13_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneph.2015.180","volume":"12","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND (2016) HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol 12(1):37\u201347","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"13_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1024\/1661-8157\/a003241","volume":"108","author":"A Jomard","year":"2019","unstructured":"Jomard A, Osto E (2019) Metabolism and Function of High-Density Lipoproteins (HDL). Praxis (Bern 1994) 108(7):477\u2013486","journal-title":"Praxis (Bern 1994)"},{"issue":"2","key":"13_CR24","first-page":"149","volume":"18","author":"TK Tosheska","year":"2017","unstructured":"Tosheska TK, Topuzovska S (2017) High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol 18(2):149\u2013154","journal-title":"Anatol J Cardiol"},{"issue":"3","key":"13_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MNH.0000000000000217","volume":"25","author":"H Yang","year":"2016","unstructured":"Yang H, Fogo AB, Kon V (2016) Kidneys: key modulators of high-density lipoprotein levels and function. Curr Opin Nephrol Hypertens 25(3):174\u2013179","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"13_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-319-09665-0_2","volume":"224","author":"VI Zannis","year":"2015","unstructured":"Zannis VI et al (2015) HDL biogenesis, remodeling, and catabolism. Handb Exp Pharmacol 224:53\u2013111","journal-title":"Handb Exp Pharmacol"},{"issue":"12","key":"13_CR27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1023\/A:1002861008363","volume":"65","author":"LE Panin","year":"2000","unstructured":"Panin LE, Russkikh GS, Polyakov LM (2000) Detection of apolipoprotein A-I, B, and E immunoreactivity in the nuclei of various rat tissue cells. Biochemistry (Mosc) 65(12):1419\u20131423","journal-title":"Biochemistry (Mosc)"},{"issue":"7","key":"13_CR28","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1172\/JCI119334","volume":"99","author":"LA Woollett","year":"1997","unstructured":"Woollett LA, Spady DK (1997) Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster. J Clin Invest 99(7):1704\u20131713","journal-title":"J Clin Invest"},{"issue":"16","key":"13_CR29","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.1074\/jbc.275.16.12003","volume":"275","author":"SM Hammad","year":"2000","unstructured":"Hammad SM et al (2000) Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem 275(16):12003\u201312008","journal-title":"J Biol Chem"},{"issue":"1","key":"13_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND (2016) Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 90(1):41\u201352","journal-title":"Kidney Int"},{"issue":"9","key":"13_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJM199008303230905","volume":"323","author":"J Joven","year":"1990","unstructured":"Joven J et al (1990) Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323(9):579\u2013584","journal-title":"N Engl J Med"},{"issue":"6","key":"13_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2362.1977.tb01652.x","volume":"7","author":"E Gherardi","year":"1977","unstructured":"Gherardi E et al (1977) Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Investig 7(6):563\u2013570","journal-title":"Eur J Clin Investig"},{"issue":"2","key":"13_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0021-9150(85)90181-9","volume":"54","author":"E Muls","year":"1985","unstructured":"Muls E et al (1985) Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 54(2):225\u2013237","journal-title":"Atherosclerosis"},{"issue":"5","key":"13_CR34","doi-asserted-by":"publisher","first-page":"F823","DOI":"10.1152\/ajprenal.2001.280.5.F823","volume":"280","author":"ND Vaziri","year":"2001","unstructured":"Vaziri ND, Liang K, Parks JS (2001) Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 280(5):F823\u2013F828","journal-title":"Am J Physiol Renal Physiol"},{"issue":"22","key":"13_CR35","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1021\/bi952242v","volume":"35","author":"Y Zhao","year":"1996","unstructured":"Zhao Y, Marcel YL (1996) Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 35(22):7174\u20137180","journal-title":"Biochemistry"},{"issue":"12","key":"13_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.clinbiochem.2007.04.016","volume":"40","author":"C Zhang","year":"2007","unstructured":"Zhang C et al (2007) Effect of hypoalbuminemia on the increased serum cholesteryl ester transfer protein concentration in children with idiopathic nephrotic syndrome. Clin Biochem 40(12):869\u2013875","journal-title":"Clin Biochem"},{"issue":"5","key":"13_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11886-016-0724-y","volume":"18","author":"B Di Bartolo","year":"2016","unstructured":"Di Bartolo B et al (2016) CETP inhibition in CVD prevention: an actual appraisal. Curr Cardiol Rep 18(5):43","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"13_CR38","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","volume":"44","author":"W Masson","year":"2018","unstructured":"Masson W et al (2018) Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes Metab 44(6):508\u2013513","journal-title":"Diabetes Metab"},{"issue":"2","key":"13_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00585.x","volume":"56","author":"K Liang","year":"1999","unstructured":"Liang K, Vaziri ND (1999) Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 56(2):621\u2013626","journal-title":"Kidney Int"},{"issue":"12","key":"13_CR40","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1073\/pnas.100114397","volume":"97","author":"M Ikemoto","year":"2000","unstructured":"Ikemoto M et al (2000) Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I. Proc Natl Acad Sci U S A 97(12):6538\u20136543","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"13_CR41","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1093\/ndt\/gfr136","volume":"26","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND et al (2011) Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor. Nephrol Dial Transplant 26(10):3118\u20133123","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"13_CR42","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1172\/JCI111548","volume":"74","author":"DW Garber","year":"1984","unstructured":"Garber DW et al (1984) Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74(4):1375\u20131383","journal-title":"J Clin Invest"},{"issue":"1","key":"13_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","volume":"10","author":"ND Vaziri","year":"2006","unstructured":"Vaziri ND, Moradi H (2006) Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 10(1):1\u20137","journal-title":"Hemodial Int"},{"issue":"5","key":"13_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrneph.2010.36","volume":"6","author":"ND Vaziri","year":"2010","unstructured":"Vaziri ND, Navab M, Fogelman AM (2010) HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6(5):287\u2013296","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"13_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000186303","volume":"57","author":"PO Attman","year":"1991","unstructured":"Attman PO, Alaupovic P (1991) Lipid and apolipoprotein profiles of uremic dyslipoproteinemia\u2014relation to renal function and dialysis. Nephron 57(4):401\u2013410","journal-title":"Nephron"},{"issue":"2","key":"13_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1681\/ASN.V52193","volume":"5","author":"VS Kamanna","year":"1994","unstructured":"Kamanna VS et al (1994) Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 5(2):193\u2013200","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"13_CR47","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","volume":"108","author":"BJ Ansell","year":"2003","unstructured":"Ansell BJ et al (2003) Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108(22):2751\u20132756","journal-title":"Circulation"},{"issue":"10","key":"13_CR48","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1172\/JCI118657","volume":"97","author":"M Klin","year":"1996","unstructured":"Klin M et al (1996) Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 97(10):2167\u20132173","journal-title":"J Clin Invest"},{"issue":"5","key":"13_CR49","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1046\/j.1523-1755.2003.00281.x","volume":"64","author":"T Sato","year":"2003","unstructured":"Sato T, Liang K, Vaziri ND (2003) Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int 64(5):1780\u20131786","journal-title":"Kidney Int"},{"issue":"2","key":"13_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","volume":"153","author":"H Moradi","year":"2009","unstructured":"Moradi H et al (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153(2):77\u201385","journal-title":"Transl Res"},{"issue":"9","key":"13_CR51","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/sj.ki.5002491","volume":"72","author":"K Kalantar-Zadeh","year":"2007","unstructured":"Kalantar-Zadeh K et al (2007) HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72(9):1149\u20131156","journal-title":"Kidney Int"},{"issue":"5","key":"13_CR52","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1681\/ASN.2011070668","volume":"23","author":"T Weichhart","year":"2012","unstructured":"Weichhart T et al (2012) Serum amyloid a in uremic HDL promotes inflammation. J Am Soc Nephrol 23(5):934\u2013947","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"13_CR53","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.numecd.2015.03.003","volume":"25","author":"PY Zuo","year":"2015","unstructured":"Zuo PY et al (2015) Non-HDL-cholesterol to HDL-cholesterol ratio as an independent risk factor for the development of chronic kidney disease. Nutr Metab Cardiovasc Dis 25(6):582\u2013587","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"13_CR54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","volume":"129","author":"FM Sacks","year":"2014","unstructured":"Sacks FM et al (2014) Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129(9):999\u20131008","journal-title":"Circulation"},{"issue":"19","key":"13_CR55","first-page":"2918","volume":"18","author":"M Liu","year":"2014","unstructured":"Liu M et al (2014) Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 18(19):2918\u20132926","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"13_CR56","first-page":"22","volume":"29","author":"V Pascual","year":"2017","unstructured":"Pascual V et al (2017) Chronic kidney disease and dyslipidaemia. Clin Investig Arterioscler 29(1):22\u201335","journal-title":"Clin Investig Arterioscler"},{"issue":"3","key":"13_CR57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238\u2013248","journal-title":"N Engl J Med"},{"issue":"4","key":"13_CR58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneph.2012.33","volume":"8","author":"M Epstein","year":"2012","unstructured":"Epstein M, Vaziri ND (2012) Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 8(4):214\u2013223","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"13_CR59","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2215\/CJN.09961110","volume":"6","author":"T Shoji","year":"2011","unstructured":"Shoji T et al (2011) Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6(5):1112\u20131120","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"13_CR60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1037\/0735-7044.101.5.732","volume":"101","author":"JW Rudy","year":"1987","unstructured":"Rudy JW, Paylor R (1987) Development of interocular equivalence of place learning in the rat requires convergence sites established prior to training. Behav Neurosci 101(5):732\u2013734","journal-title":"Behav Neurosci"},{"issue":"7","key":"13_CR61","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1194\/jlr.P085076","volume":"59","author":"K Untersteller","year":"2018","unstructured":"Untersteller K et al (2018) HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients. J Lipid Res 59(7):1256\u20131265","journal-title":"J Lipid Res"}],"container-title":["Advances in Experimental Medicine and Biology","HDL Metabolism and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-19-1592-5_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T14:03:40Z","timestamp":1668348220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-19-1592-5_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9789811915918","9789811915925"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/978-981-19-1592-5_13","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"17 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}